Milestone Pharmaceuticals Inc. MIST
Regular-session close
After hours · Nov 20, 4:06 PM ET
- YTD
- -81.63%
- 1 year
- -83.94%
5D -0.1104 (-22.53%)
- Market cap
- 46.20M
- EPS (ttm)
- -0.74
- Shares out
- 53.33M
- Forward P/E
- -2.15
- YTD return
- -81.63%
- 1-year return
- -83.94%
- 50-day average
- 1.71
- 200-day average
- 1.58
- Volume
- 1.53M
- Avg volume
- 1.54M
- Open
- 0.384
- Previous close
- 0.3993
- Day's range
- 0.3705 – 0.40
- 52-week range
- 0.362 – 3.06
- Beta
- 1.73
- Price target
- 10.25 (+2662.1%)
Key statistics
- Enterprise value
- 93.76M
- Price / book
- 4.76
- Free cash flow
- -23.84M
- Total cash
- 83.25M
- Total debt
- 53.25M
- Return on equity
- -133.75%
- Short % of float
- 0.86%
Fundamental scorecard
6 of 25 checks passed on MIST’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | -0.14 | +0.05 | +26.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.26 | -0.21 | +0.05 | +19.23% |
| May 13, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.30 | -0.32 | -0.02 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | init | — | Buy |
| Jul 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- milestonepharma.com
News
Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results
Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5
Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $3
HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $6
Milestone Pharmaceuticals Inc. (MIST) Q3 2026 Earnings Call Transcript
Milestone Pharmaceuticals Q3 Earnings Call Highlights
Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates Milestone Pharmaceuticals Announces Cost-Efficiency Measures To Reduce Its Opex By ~30%, Completed By Q1 2027; Expects To Incur ~$2M In One-Time Charges
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
Your note
Sign in to keep a note on MIST — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.32% | 4,971,344 | 9.20M | Sep 29, 2024 |
| RTW Investments LP | 6.11% | 3,256,102 | 6.02M | Sep 29, 2024 |
| Millennium Management Llc | 5.21% | 2,778,525 | 5.14M | Sep 29, 2024 |
| Alta Fundamental Advisers LLC | 4.99% | 2,658,589 | 4.92M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.87% | 2,061,522 | 3.81M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 3.75% | 2,000,000 | 3.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.04% | 19,311 | 35.73K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 17,576 | 32.52K | Oct 30, 2024 |
| JNL Series Trust-JNL/DFA U.S. Small Cap Fund | 0.00% | 1,661 | 3.07K | Sep 29, 2024 |
